SCHEMBL5175236

SCHEMBL5175236

CC(C)[C@H](NC(=O)OCc1ccccc1Cl)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
HPGD P15428 1/20 0.53
CYP2C19 P33261 1/20 0.53
POLB P06746 1/20 0.48
TYR P14679 1/20 0.47
MEN1 O00255 1/20 0.47
PKM P14618 1/20 0.47
CASP3 P42574 1/20 0.47
KMT2A Q03164 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
ECE1 P42892 2/20 0.46
MME P08473 1/20 0.46
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9439010 0.91 CYP1A2 (0.52) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5175239 0.85 TYR (0.48) ALDH1A1HPGDPOLBTYRECE1
SCHEMBL6150075 0.84 ECE1 (0.48) ALDH1A1HPGDPOLBTYRMEN1
SCHEMBL8145861 0.82 CYP1A2 (0.48) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8671882 0.81 CTSL (0.63) MEN1CASP3KMT2AECE1MME
SCHEMBL220569 0.81 CTSL (0.63) MEN1CASP3KMT2AECE1MME
SCHEMBL1287168 0.81 CTSL (0.63) MEN1CASP3KMT2AECE1MME
SCHEMBL2978398 0.81 CTSL (0.63) MEN1CASP3KMT2AECE1MME
SCHEMBL19607509 0.78 CTSL (0.55) TYRMEN1CASP3KMT2AECE1
Isopropylamine SCHEMBL10558459 0.78 CTSL (0.59) CASP3ECE1MMECTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1494700-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS Cytovia, Inc. (US) 2005-01-12 EP claimed
WO-2004002401-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS CYTOVIA, INC. (US) 2004-01-08 WO claimed
EP-1177168-B1 CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA INC (US) 2007-05-30 EP disclosed
US-20040116355-A1 Caspase inhibitors and the use thereof CYTOVIA, INC. 2004-06-17 US disclosed
US-6716818-B2 DIPEPTIDE DERIVATIVES CYTOVIA, INC. 2004-04-06 US disclosed
EP-1177168-A4 CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA INC (US) 2003-06-25 EP disclosed
US-20020058631-A1 Caspase inhibitors and the use thereof CYTOVIA, INC. 2002-05-16 US disclosed
US-6355618-B1 ENZYME INHIBITORS CYTOVIA, INC. 2002-03-12 US disclosed
EP-1177168-A1 CASPASE INHIBITORS AND THE USE THEREOF Cytovia, Inc. (US) 2002-02-06 EP disclosed
WO-2000061542-A1 CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA, INC. (US) 2000-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058631-A1 Caspase inhibitors and the use thereof CASP1, CASP3, CASP10 ALDH1A1 2519/4885CYP1A2 3277/4885CYP3A4 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.